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Melioidosis is a potentially fatal disease caused by Burkholderia pseudomallei 
which is endemic in Malaysian Borneo. The general aim of this study is to 
elucidate the molecular epidemiology of B. pseudomallei in Malaysian Borneo. 
Consistent with the Wallace line theory of separation, genotyping showed 
Malaysian Borneo clinical B. pseudomallei isolates were more related to 
Southeast Asian strains than to Australian strains. Whole genome sequencing 
demonstrated that B. pseudomallei from Sarawak were very closely related to 
each other. Biochemical testing using VITEK 2 revealed that 25% of B. 
pseudomallei from Malaysian Borneo were misidentified as B. cepacia, 
suggesting that specificity of that identification system is regionally dependent. A 
major and unexpected finding was that 88% of Sarawak B. pseudomallei were 
gentamicin susceptible, with these B. pseudomallei being restricted to multilocus 
sequence type ST881 and its single locus variant ST997. A novel non-
synonymous mutation was identified within amrB, an essential component of the 
AmrAB-OprA multi-drug efflux pump. Reversion of the mutation to the wild-type 
sequence confirmed the role of this mutation in conferring aminoglycoside and 
macrolide sensitivity. No environmental B. pseudomallei were isolated from 
Sarawak but other Burkholderia species were isolated, prompting the formulation 
of hypotheses to explain the lack of environmental B. pseudomallei. Although 
inconclusive, experiments showed antagonistic activities by other environmental 
Burkholderia spp. recovered from environmental sampling studies towards B. 
pseudomallei and also that gentamicin susceptible B. pseudomallei were slightly 
xiv 
 
less robust than gentamicin resistant strains in competing with other soil 
microorganisms. This thesis contributed to the understanding of the population 
structure of B. pseudomallei in Malaysian Borneo, Southeast Asia and globally. 
The discovery of gentamicin susceptibility in Sarawak B. pseudomallei has 
significant implications for laboratory diagnosis and environmental sampling of B. 
pseudomallei in Malaysian Borneo and potentially in other melioidosis endemic 
regions. Although the exact distributions, quantification and potential 
environmental hazards and implications of B. pseudomallei in Malaysian Borneo 
remain uncertain, these studies have led to important research questions now to be 
explored. Most immediate is further searching for the proposed existence of an as 
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1.1 General introduction: Burkholderia pseudomallei and melioidosis 
1.1.1 Burkholderia genus 
The Burkholderia genus was formed in 1992 when seven members of the 
Pseudomonas species were transferred over to the newly formed Burkholderia 
genus (Yabuuchi et al., 1992). The name “Burkholderia” was coined to honour 
Walter Burkholder who discovered Pseudomonas cepacia which caused onion 
diseases in the 1940s and 1950s (Yabuuchi et al., 1992, Coenye and Vandamme, 
2007). To date, the Burkholderia genus has over 60 species residing in diverse 
ecologies including environmental and biological niches 
(http://www.bacterio.net/burkholderia.html)(Coenye and Vandamme, 2003, 
Vandamme and Dawyndt, 2011). Most Burkholderia species (spp.) are considered 
plant pathogens, plant commensals and soil bacteria, but some have the ability to 
cause infections in humans and animals (Coenye et al., 2001, Coenye and 
Vandamme, 2003, Coenye and Vandamme, 2007, Mahenthiralingam et al., 2005). 
There are 17 closely related Burkholderia spp. that are categorised as 
Burkholderia cepacia complex (Bcc). While some Bcc members are considered 
plant pathogens, others are plant commensals and also bioremediation agents 
which degrade environmental pollutants (Mahenthiralingam et al., 2005). In 
addition to their roles in plants and environments, some Bcc have been reported to 
cause opportunistic infection in both immunocompromised and cystic fibrosis 
(CF) patients (Coenye and Vandamme, 2003, Coenye and Vandamme, 2007, 
Vandamme and Dawyndt, 2011).  
 
1.1.2 Burkholderia pseudomallei 
Burkholderia pseudomallei is the bacterium that causes melioidosis which was 
first described by Whitmore and Krishnaswami in Rangoon, Burma in 1911 
(Whitmore and Krishnaswami, 1912). Due to the resemblance of the bacterium to 
Bacillus mallei which causes glanders disease, it was named Bacillus 
pseudomallei. Over the years, the bacterium was also known by different names 
such as Bacillus whitmorii (Bacille de Whitmore in French), Malleomyces 
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pseudomallei, Pseudomonas pseudomallei and finally B. pseudomallei in 1992 
(Yabuuchi et al., 1992). It is a non-spore forming motile gram-negative bacillus 
with bipolar staining, often described as resembling a safety pin in a Gram stain 
(Cheng and Currie, 2005). The genome of B. pseudomallei is comprised of two 
circular chromosomes with a combined length of 7.2 mega base-pairs (Mbp), 
encompassing approximately 5800 genes (Holden et al., 2004, Nandi et al., 2010). 
Chromosome 1 contains housekeeping genes for macromolecular biosynthesis, 
amino acid metabolism, cofactor and carrier synthesis, nucleotide and protein 
biosynthesis, chemotaxis, and mobility. Chromosome 2 contains genes for 
accessory functions such as adaptations to atypical conditions, iron homeostasis, 
secondary metabolism, regulation and horizontal gene transfer (Holden et al., 
2004). Due in part to the high virulence of this organism and increased concerns 
for transmission by aerosolization, B. pseudomallei was classified as a Tier 1 
select agent by the U.S. Centres for Disease Control and Prevention (US CDC) in 
2012 (http://www.selectagents.gov/). 
 
B. pseudomallei is closely related to two other Burkholderia spp. namely 
Burkholderia thailandensis and Burkholderia mallei (Brett et al., 1998, Nierman 
et al., 2004). Despite its high genomic similarities to B. pseudomallei, B. 
thailandensis is an avirulent soil bacterium that is able to utilize arabinose as a 
sole energy source (Brett et al., 1998, Trakulsomboon et al., 1999). B. mallei is a 
zoonotic host-adapted pathogen affecting mainly equines and causes glanders 
disease (Nierman et al., 2004). Studies showed that B. mallei evolved from a 
single strain of B. pseudomallei ancestor through erosion of nonessential genomes 
responsible for environmental survival and became completely host-adapted. It 
was also shown that the genome of B. mallei is approximately 1.5 Mbp smaller 
than that of its ancestor (Godoy et al., 2003, Nierman et al., 2004, Losada et al., 
2010). 
 
B. pseudomallei is commonly found in the soil and water of melioidosis endemic 
regions, which include Southeast Asian countries, northern Australia and other 
tropical regions (White, 2003, Cheng and Currie, 2005). As more melioidosis 
areas are discovered, the knowledge on global distribution will keep expanding 




Coined by Stanton and Fletcher in 1921, melioidosis was derived from Greek 
which means ‘distemper of asses’ (Stanton and Fletcher, 1921). Patients with 
melioidosis can present with a spectrum of clinical presentations including 
localized skin abscess, acute or chronic pneumonia, genitourinary, bone, and joint 
infections and severe systemic sepsis (with or without foci of multiple abscesses 
in internal organs). Patients with septic shock may have a mortality of >90% 
(White, 2003, Cheng and Currie, 2005). Asymptomatic and chronic infections 
have been reported where the organism has been shown to evolve within the host 
(Price et al., 2010, Price et al., 2013a).  
 
Mode of acquisition 
The mode of acquisition of melioidosis is via percutaneous inoculation, inhalation 
or ingestion of B. pseudomallei contaminated wet soil or surface water or aerosols 
(Puthucheary and Vadivelu, 2002, Cheng and Currie, 2005, Wiersinga et al., 
2012).  
 
Inoculation has been suggested to be the main mode of acquisition. Individuals 
with occupational risks such as farmers and construction workers were reportedly 
exposed to B. pseudomallei through open wound or penetrating injuries 
(Chaowagul et al., 1989, Cheng and Currie, 2005, Kaestli et al., 2009, Wiersinga 
et al., 2012). In a study in the Top End, Australia, 25% of melioidosis patients 
were shown to have some history of inoculation via skin breakage prior to disease. 
Despite being acquired through skin inoculation, the range of disease in the 
patients in this study was not confined to mere subcutaneous symptoms as many 
patients presented with more severe illnesses (Currie et al., 2000b).  
 
Inhalation was implicated as the primary mode of acquisition for melioidosis 
cases amongst helicopter crews of the United States armies in Vietnam in the 
1960s (Howe et al., 1971). Since then, inhalation has been considered to be an 
important mode of acquisition especially during increased heavy rainfall and 
during extreme weather events such as strong winds, cyclones or typhoons 
(Puthucheary and Vadivelu, 2002, Currie and Jacups, 2003, Ko et al., 2007, Lo et 
al., 2009, Su et al., 2011) . 
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The first implication of ingestion as a mode of acquisition was by Stanton and 
Fletcher in 1925 (Stanton and Fletcher, 1925). Although this route has not been 
described much in detail, reports of melioidosis outbreaks due to contaminated 
water supply have implicated ingestion as a mode of acquisition (Inglis et al., 
1999, Currie et al., 2001). The high incidence of suppurative parotitis amongst 
paediatric patients mainly in South East Asia has been suggested to be associated 
with ingestion (Dance et al., 1989a) and a recent case control study from Thailand 
has supported this, together with the high rates of recovery of B. pseudomallei 
from domestic water supplies in that study (Limmathurotsakul et al., 2013b). 
 
B. pseudomallei acquisition has also been associated with tsunami where 
survivors of the disaster in affected countries were presented with various 
symptoms including cutaneous infection, pulmonary involvement and septicaemia 
(Allworth, 2005, Athan et al., 2005, Chierakul et al., 2005, Nieminen and Vaara, 
2005, Svensson et al., 2006, Othman et al., 2007, Currie et al., 2008, Arzola et al., 
2007). 
 
Other modes of acquisition are via laboratory-acquired infection (Green and 
Tuffnell, 1968, Schlech et al., 1981), contaminated detergent and other medical 
supplies (Punyagupta, 1989, Gal et al., 2004), breast milk (Ralph et al., 2004), 
person-to-person transmission (McCormick et al., 1975, Holland et al., 2002), 
possible sexual transmission (McCormick et al., 1975, Webling, 1980) and intra-
uterine transmission (Abbink et al., 2001). Although rare, zoonotic human 
infections have also been reported (Low Choy et al., 2000).  
 
Treatment of melioidosis 
Due to both the intracellular nature of the organism after infection and its 
potential for latency, there are two phases in melioidosis treatment; a short-term 
intensive acute phase and a long-term oral eradication phase (Wiersinga et al., 
2012). In general, the intensive acute phase treatment involves bactericidal drugs 
with or without post-antibiotic effect, while the eradication phase treatment 
involves bacteriostatic drugs (Estes et al., 2010, Wiersinga et al., 2012). The 
current recommended treatment of melioidosis consists of an intensive phase of at 
least 10 to 14 days of intravenous ceftazidime, meropenem, or imipenem, 
5 
 
followed by oral eradication therapy of trimethoprim–sulfamethoxazole for three 
to six months (Wiersinga et al., 2012). 
 
Drug susceptibility and resistance 
B. pseudomallei is intrinsically resistant to numerous antibiotics including first-
generation and second-generation quinolones, all narrow-spectrum 
cephalosporins, all macrolides, most penicillins, all polymyxins, and 
aminoglycosides (Livermore et al., 1987, Dance et al., 1989c, Dance et al., 1989b, 
Jenney et al., 2001, Estes et al., 2010, Wuthiekanun et al., 2011), which limits 
treatment options for melioidosis. Although rare, aminoglycosides and macrolides 
sensitivity has been reported (Simpson et al., 1999, Trunck et al., 2009, Podin et 
al., 2014). B. pseudomallei is generally susceptible to carbapenems, some 
fluoroquinolones, and amoxicillin-β-lactamase inhibitor combinations, 
chloramphenicol, tetracyclines and trimethoprim-sulfonamides in vitro (Ashdown, 
1988, Dance et al., 1989c, Wuthiekanun et al., 2011). However, clinical studies 
have shown that fluoroquinolones are associated with higher treatment failure 
rates (Chaowagul et al., 1997, Chetchotisakd et al., 2001, Steward et al., 2005, 
Wuthiekanun et al., 2011). Although uncommon, acquired resistance to 
ceftazidime during therapy has been documented and genetically characterised 
(Jenney et al., 2001, Chantratita et al., 2011, Sarovich et al., 2012a, Sarovich et 
al., 2012b). 
 
Relapse of melioidosis 
Relapse in melioidosis upon completion of treatment has been well documented 
(Puthucheary and Vadivelu, 2002, White, 2003, Cheng and Currie, 2005, Sarovich 
et al., 2014b). There have also been reports of reactivation of melioidosis for as 
long as 62 years after primary exposure to the causative agent (Ngauy et al., 
2005). The propensity for relapse is caused by factors such as poor adherence to 
treatment, severe diseases, inadequate use of drug type during the intensive and 
eradication phase, and eradication phase of less than eight weeks (Chaowagul et 
al., 1993, Currie et al., 2000a). While most of the relapse cases were associated 
with reactivation of the original infecting strain, re-infection with a different strain 
has also been reported (Desmarchelier et al., 1993, Vadivelu et al., 1998, Currie et 
al., 2000a, Sarovich et al., 2014b).  
